Ritter Pharmaceuticals Inc (NASDAQ:RTTR)’s share price reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $1.68 and last traded at $1.70, with a volume of 600 shares changing hands. The stock had previously closed at $1.89.
Several research firms recently issued reports on RTTR. Zacks Investment Research cut Ritter Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, July 18th. HC Wainwright set a $15.00 price target on Ritter Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, June 6th.
The firm has a market cap of $10.74 million, a PE ratio of -0.34 and a beta of 0.63.
Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.15). equities analysts expect that Ritter Pharmaceuticals Inc will post -2.97 earnings per share for the current year.
In related news, Director Matthew W. Foehr bought 19,751 shares of the business’s stock in a transaction on Friday, August 17th. The shares were purchased at an average price of $2.04 per share, with a total value of $40,292.04. Following the completion of the purchase, the director now owns 54,751 shares of the company’s stock, valued at approximately $111,692.04. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Corporate insiders own 21.60% of the company’s stock.
Ritter Pharmaceuticals Company Profile (NASDAQ:RTTR)
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Recommended Story: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.